Identifying aggressive versus non-aggressive prostate cancer using genomic markers
Genomic marker to distinguish aggressive and indolent prostate cancer
This study is looking at a special marker in prostate cancer that can help doctors tell if a tumor is aggressive or not, so they can better decide if men with low-risk prostate cancer need treatment right away or if they can just be watched closely.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biomarker Corporation NIH-funded |
| Lab location | 1 site (South San Francisco, United States) |
| Project ID | NIH-10820859 on NIH RePORTER |
What this research studies
This research investigates a genomic marker called GEMCaP that helps distinguish between aggressive and indolent forms of prostate cancer. By analyzing tumor DNA from biopsies, the study aims to improve treatment decisions for men diagnosed with prostate cancer, particularly those classified as low-risk. The goal is to identify which tumors may require immediate treatment and which can be safely monitored through Active Surveillance. This approach could lead to more personalized and effective management of prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with low-risk prostate cancer who are considering Active Surveillance.
Not a fit: Patients with aggressive prostate cancer or those who have already undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better treatment decisions for prostate cancer patients, reducing unnecessary surgeries and associated side effects.
How similar studies have performed: Previous research has shown promise in using genomic markers for cancer diagnosis, suggesting that this approach could be effective.
Where this research is happening
South San Francisco, United States
- Biomarker Corporation — South San Francisco, United States (Active)
Researchers
- Principal investigator: Davis, Randall — Biomarker Corporation
- Study coordinator: Davis, Randall
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.